The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

2.

For treatment, the majority of cancer patients choose complementary therapies.

3.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

4.

A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.

5.

Rural-urban disparities seen in cervical cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot